Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists had similar rates of other adverse events, including bone fracture, acute kidney injury, serious urinary tract infection, venous thromboembolism, and
Compared to young adults without diabetes, those with diabetes were more likely to have obesity, elevated lipids, or hypertension and were less likely to report being physically active or consuming a healthy diet.
The findings may reassure prescribers of dipeptidyl peptidase-4 inhibitors that the drug class does not significantly increase the risk of adverse pancreatic outcomes compared with other second-line therapies, study authors said.
The studied risk factors were HbA1c level, LDL cholesterol level, presence of albuminuria, smoking status, and blood pressure.
A retrospective study of Canadian and British patients with type 2 diabetes found lower rates of cardiovascular death among those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors than in matched patients who took dipeptidyl peptidase-4
The findings underscore the urgency of early diagnosis of diabetes and the consequences of failing to achieve near-normal glycemia soon after patients are diagnosed, according to the study authors.
In a retrospective observational study, patients with prediabetes were assigned to a risk category for diabetes based on presence and severity of insulin resistance, impaired beta-cell function, and hyperglycemia, then treated accordingly.
Among patients with coronary artery disease, severity and frequency of hypoglycemia were associated with increased levels of high-sensitivity cardiac troponin T, although the association was attenuated in adjusted analyses.
The guideline, developed by the Joint British Diabetes Societies for Inpatient Care, noted that many patients taking insulin will know more about their usual regimen than the medical and nursing staff responsible for their care.
The American Diabetes Association calls for increasing transparency across the entire supply chain, streamlining the approval process for biosimilars, lowering or removing patient cost-sharing, and increasing access to health care coverage for